$0.33
-$0.00 (-1.00%)
$0.31Day Range$0.34
Key Statistics
Market Cap
$48.68M
Shares Outstanding
147.4M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Jan 1, 1988
Round Lot
100
Locale
US
Trading Data
Day Open
$0.34
Day High
$0.34
Day Low
$0.31
Volume
256.7K
VWAP
$0.33
Prev Close
$0.33
Transactions
--
Acc. Volume
--
About Immutep Limited American Depositary Shares
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Identifiers
- CIK
- 0001506184
- Composite FIGI
- BBG002WD6SY6
- Share Class FIGI
- BBG002WD6TP4
- Ticker Root
- IMMP
About Immutep Limited American Depositary Shares (IMMP) Stock
Immutep Limited American Depositary Shares (IMMP) closed the 2026-09-16 session at $0.33, down 1.00% versus the previous close (-0.00). The stock opened at $0.34 and traded between $0.31 and $0.34 during that session. Session trading volume was 257K shares. The volume-weighted average price (VWAP) is $0.33.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Immutep Limited American Depositary Shares has a market capitalization of $48.7 million. IMMP is listed on the XNAS exchange. The company employs approximately 51 people. The recorded listing date is 1988-01-01.
On this page you can find market IMMP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.